Molecular Imaging Shows Promise for Predicting Treatment Response in HER2-Positive Breast Cancer

A new molecular imaging technique using ⁶⁸Ga-HER2 PET/CT scans may help doctors determine early how well treatment is working in patients with HER2-positive breast cancer. This targeted imaging approach provides real-time assessment of treatment effectiveness, potentially allowing physicians to adjust therapy strategies quickly if needed. Early prediction of complete pathologic response could significantly improve outcomes by personalizing treatment plans based on individual patient response. This advancement represents an important step toward precision medicine in breast cancer care, offering hope to patients seeking more effective and individualized treatment options.